Trials / Recruiting
RecruitingNCT04794972
A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors
An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability，Pharmacokinetic/Pharmacodynamics and Anti-tumor Activity of Tetra-specific Antibody GNC-039 in Participants With Relapsed/Refractory or Metastatic Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this study, the safety, tolerability and preliminary effectiveness of GNC-039 in patients with relapsed/refractory or metastatic glioma or other solid tumors will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-039.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GNC-039 | Administration by intravenous infusion. |
Timeline
- Start date
- 2021-04-14
- Primary completion
- 2025-12-01
- Completion
- 2026-12-01
- First posted
- 2021-03-12
- Last updated
- 2025-09-29
Locations
6 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04794972. Inclusion in this directory is not an endorsement.